Retatrutide (LY-3437943) is an investigational peptide designed as a single-molecule triple agonist at the GLP-1, GIP, and glucagon receptors. By activating all three incretin and glucagon pathways simultaneously, it influences appetite, glycemic control, and energy expenditure through complementary mechanisms.
Clinical research has examined Retatrutide for body-weight reduction and metabolic outcomes in obesity and type 2 diabetes models. Trial readouts have reported some of the strongest body-composition effects in the GLP-1-adjacent class to date.
- Multi-pathway weight-management research (GLP-1 + GIP + glucagon)
- Glucose control and insulin-sensitivity studies
- Energy expenditure and thermogenesis investigation
- Metabolic-syndrome and lipid-profile research
- Purity
- 99.55% (HPLC)
Store between 2 °C and 8 °C, away from light. Do not freeze reconstituted product. Avoid moisture exposure.
For research and laboratory use only. Not for human or veterinary consumption.
How to run this compound.
Add bacteriostatic water to the sealed vial. Swirl — do not shake. Refrigerate after reconstitution.
Reconstitute with bacteriostatic water. Subcutaneous administration on protocol cadence.
Run on the protocol schedule. The system rewards consistency over intensity.
Pair with complementary REFRAME lines. See suggestions below.
